Year |
Citation |
Score |
2020 |
Sharma A, Li M, Thavathiru E, Ibrahim M, Garcia-Contreras L, Benbrook DM, Woo S. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. The Aaps Journal. 22: 51. PMID 32086622 DOI: 10.1208/S12248-020-0421-Z |
0.367 |
|
2020 |
Lim SY, Sharan S, Woo S. Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability. Pharmacotherapy. PMID 32058609 DOI: 10.1002/Phar.2377 |
0.304 |
|
2019 |
Subramaniyan B, Rajaputra P, Nguyen L, Li M, Peer CJ, Kindrick J, Figg WD, Woo S, You Y. Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. Photochemistry and Photobiology. PMID 31883393 DOI: 10.1111/Php.13202 |
0.308 |
|
2019 |
Nguyen L, Li M, Woo S, You Y. Development of Prodrugs for PDT-Based Combination Therapy Using a Singlet-Oxygen-Sensitive Linker and Quantitative Systems Pharmacology. Journal of Clinical Medicine. 8. PMID 31847080 DOI: 10.3390/Jcm8122198 |
0.315 |
|
2019 |
Li M, Nguyen L, Subramaniyan B, Bio M, Peer CJ, Kendrick J, Figg WD, Woo S, You Y. PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31299262 DOI: 10.1016/J.Jconrel.2019.07.010 |
0.35 |
|
2018 |
Sharma A, Benbrook DM, Woo S. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. Plos One. 13: e0194046. PMID 29634717 DOI: 10.1371/Journal.Pone.0194046 |
0.356 |
|
2017 |
Ibach BW, Miller JL, Woo S, Harrison D, Standifer KM, Hagemann T, Johnson PN. Characterization of Tolerance in Children during Fentanyl Continuous Infusions. Journal of Pediatric Intensive Care. 6: 83-90. PMID 31073429 DOI: 10.1055/S-0036-1584909 |
0.301 |
|
2017 |
Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. Journal of Pharmacokinetics and Pharmacodynamics. PMID 28913666 DOI: 10.1007/S10928-017-9543-Z |
0.35 |
|
2016 |
Thapa P, Li M, Bio M, Rajaputra P, Sun Y, Woo S, You Y. Abstract 1361: Progress in light activatable prodrug for the combinational treatment of PDT and site-specific chemotherapy: paclitaxel prodrugs Cancer Research. 76: 1361-1361. DOI: 10.1158/1538-7445.Am2016-1361 |
0.316 |
|
2015 |
Devapatla B, Sharma A, Woo S. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. Plos One. 10: e0139237. PMID 26414070 DOI: 10.1371/Journal.Pone.0139237 |
0.329 |
|
2015 |
Sharan S, Woo S. Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Frontiers in Pharmacology. 6: 33. PMID 25750626 DOI: 10.3389/Fphar.2015.00033 |
0.327 |
|
2015 |
Devapatla BK, Jaiprasart P, Woo S. Abstract 1935: Gene expression analysis reveals distinct pathways of resistance to antiangiogenic therapy in ovarian cancer Cancer Research. 75: 1935-1935. DOI: 10.1158/1538-7445.Am2015-1935 |
0.32 |
|
2014 |
Devapatla BK, Sharma A, Woo S. Abstract 2999: Interleukin-8 mediates resistance to anti-VEGF therapy in ovarian cancer Cancer Research. 74: 2999-2999. DOI: 10.1158/1538-7445.Am2014-2999 |
0.309 |
|
2013 |
Vega-Villa K, Ihnat M, Woo S. Abstract 2065: Development of a general framework for effective translation of in vitro synergistic combination into in vivo synergy using a systemic modeling approach. Cancer Research. 73: 2065-2065. DOI: 10.1158/1538-7445.Am2013-2065 |
0.382 |
|
2012 |
Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2344-51. PMID 22371451 DOI: 10.1158/1078-0432.Ccr-11-2425 |
0.306 |
|
2011 |
Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, Devroom HL, Nahavandi M, Woo S, Figg WD, Lonser RR. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. Plos One. 6: e14504. PMID 21249218 DOI: 10.1371/Journal.Pone.0014504 |
0.315 |
|
2011 |
Kaneda K, Yamashita S, Woo S, Han TH. Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. Journal of Clinical Pharmacology. 51: 482-91. PMID 20498288 DOI: 10.1177/0091270010369242 |
0.32 |
|
2009 |
Woo S, Pawaskar D, Jusko WJ. Methods of utilizing baseline values for indirect response models. Journal of Pharmacokinetics and Pharmacodynamics. 36: 381-405. PMID 19697107 DOI: 10.1007/S10928-009-9128-6 |
0.652 |
|
2009 |
Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. Journal of Clinical Pharmacology. 49: 650-60. PMID 19451403 DOI: 10.1177/0091270009335001 |
0.331 |
|
2009 |
Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metabolism and Pharmacokinetics. 24: 16-24. PMID 19252333 DOI: 10.2133/Dmpk.24.16 |
0.598 |
|
2008 |
Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. Journal of Clinical Pharmacology. 48: 43-52. PMID 18025524 DOI: 10.1177/0091270007309702 |
0.442 |
|
2008 |
Woo S, Krzyzanski W, Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemotherapy and Pharmacology. 62: 123-33. PMID 17891399 DOI: 10.1007/S00280-007-0582-9 |
0.487 |
|
2007 |
Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). Journal of Pharmacokinetics and Pharmacodynamics. 34: 849-68. PMID 17943422 DOI: 10.1007/S10928-007-9074-0 |
0.514 |
|
2007 |
Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1672-8. PMID 17576810 DOI: 10.1124/Dmd.107.015248 |
0.494 |
|
2006 |
Woo S, Krzyzanski W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. The Journal of Pharmacology and Experimental Therapeutics. 319: 1297-306. PMID 16973883 DOI: 10.1124/Jpet.106.111377 |
0.522 |
|
2006 |
Krzyzanski W, Woo S, Jusko WJ. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. Journal of Pharmacokinetics and Pharmacodynamics. 33: 125-66. PMID 16565883 DOI: 10.1007/S10928-006-9007-3 |
0.467 |
|
Show low-probability matches. |